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Abstract
Lorvotuzumab mertansine (LM, IMGN901) is a CD56-targeting antibody-drug conjugate developed for tumor-
selective delivery of the cytotoxic maytansinoid DM1. This phase 1/2 study evaluated the combination of LM
with ﬁrst-line carboplatin/etoposide chemotherapy in patients with extensive-disease small-cell lung cancer.
Overall, modest improvements in patient tumor responses did not outweigh the increased safety risks of the
triplet combination.
Introduction: This trial assessed the safety and efﬁcacy of LM in combination with carboplatin/etoposide therapy
compared to carboplatin/etoposide treatment alone in patients with previously untreated extensive-disease small-cell
lung cancer (ED-SCLC). Patients and Methods: A run-in phase 1 stage was used to determine the recommended
phase 2 dose and characterize the dose-limiting toxicities of LM in combination with carboplatin/etoposide followed
by LM alone in patients with CD56-positive solid tumors. In phase 2, chemotherapy-naive ED-SCLC patients were
randomized 2:1 to carboplatin AUC (area under the plasma concentration vs. time curve) of 5 day 1 þ etoposide 100
mg/m2 days 1 to 3 plus LM (arm 1) or alone (arm 2). Results: In the phase 1 study (n ¼ 33), a dose of LM at 112 mg/m2
with carboplatin/etoposide was identiﬁed as the recommended phase 2 dose. However, because of an increased
incidence of peripheral neuropathy events during early phase 2, this dose was reduced to 90 mg/m2. In phase 2, a total
of 94 and 47 evaluable patients were assigned to arms 1 and 2, respectively. No difference in median progression-free
survival was observed between arms 1 and 2 (6.2 vs. 6.7 months). The most common treatment-emergent adverse
event leading to discontinuation was peripheral neuropathy (29%). A total of 21 patients had a treatment-emergent
adverse event leading to death (18 in arm 1 and 3 in arm 2); for 10 individuals, this was an infection (pneumonia or
sepsis) deemed to be related to the study drug. Conclusion: The combination of LM plus carboplatin/etoposide did
not improve efﬁcacy over standard carboplatin/etoposide doublet therapy in ED-SCLC patients and showed increased
toxicity, including a higher incidence of serious infections with fatal outcomes.
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Study of Lorvotuzumab MertansineIntroduction randomized phase 2 design comparing LM combination therapy to
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine
tumor that accounts for approximately 15% of all lung cancer
cases.1 SCLC has a high propensity to metastasize early during
disease development. At diagnosis, it is classiﬁed into either limited-
stage disease (LD) or extensive-stage disease (ED). LD-SCLC is
characterized by tumor conﬁnement, generally to one hemithorax
and encompassable in a single radiation ﬁeld. A majority of patients
(w70%), however, present with extensive-disease small-cell lung
cancer (ED-SCLC), showing dissemination beyond this region,
most commonly to the contralateral lung, liver, brain, and bones.2
Treatment strategies for SCLC have changed little over recent
decades,3 with concurrent chemoradiation or chemotherapy alone
providing the foundations for LD-SCLC and ED-SCLC standard of
care, respectively.4 Thoracic radiotherapy, preferably administered
early during the initial cycles of chemotherapy, plays an indis-
pensable role in the treatment of LD-SCLC.4 The ability of
radiotherapy to improve outcomes for individuals with ED-SCLC,
however, either in the consolidative or prophylactic settings, is less
well established.5 Thus, etoposide in combination with a platinum
agent (carboplatin or cisplatin) remains the standard ﬁrst-line option
for ED-SCLC patients.6 Despite a high likelihood of initial response
to therapy, most patients eventually experience relapse with resistant
disease. Median overall survival (OS) times of only 8 to 11 months
are achieved with standard therapies.7 In an effort to improve
outcomes in ED-SCLC, a number of alternative approaches have
been evaluated, such as 3-drug combinations, sequential combina-
tion therapies, and dose-intensiﬁed schedules.8-10 To date, none of
these alternate modalities has demonstrated a signiﬁcant survival
advantage over current combination therapy; the development of
new strategies to effectively combat SCLC thus represents a critical
unmet medical need.
Lorvotuzumab mertansine (LM, IMGN901) is an antibody-drug
conjugate comprising a humanized anti-CD56 monoclonal anti-
body (huN901, lorvotuzumab) covalently coupled, via disulﬁde
linkage, to the cytotoxic maytansinoid DM1.11 CD56, also known
as NCAM1, is a member of the neural cell adhesion molecule
family12 that is primarily expressed on natural killer cells and T-cell
lineages.13 Aberrant CD56 expression is also observed in a variety of
human cancers, and for solid tumors, it serves as a diagnostic
biomarker to identify those of neuroendocrine origin, including
SCLC.14-16 LM binds with high afﬁnity and speciﬁcity to CD56 on
the surface of tumor cells, resulting in internalization of the
antibody-drug conjugate and subsequent intracellular release of
DM1 due to cleavage of its disulﬁde bond with the linker.17 This in
turn promotes disruption of microtubule assembly, G2/metaphase
arrest, and ultimately apoptosis.18-20 In preclinical studies, LM has
shown robust antitumor activity in CD56-positive tumors, most
notably in models of SCLC.21 Further, preliminary signs of efﬁcacy
have been observed in SCLC patients undergoing LM monotherapy
as part of a phase 1 study in patients with CD56-positive solid
tumors.22
Here we report the ﬁndings of an open-label, multicenter phase
1/2 study designed to assess the safety and efﬁcacy of LM when
administered in combination with carboplatin/etoposide doublet
therapy. The dose-ﬁnding phase 1 component was a lead-in to anical Lung Cancer Month 2016carboplatin/etoposide treatment alone in ED-SCLC patients.
Patients and Methods
Patients
For the phase 1 portion of the trial, patients with advanced solid
tumors for whom treatment with carboplatin/etoposide was a
reasonable therapeutic option were eligible to participate. Only
patients with histologically or cytologically conﬁrmed ED-SCLC
and who were chemotherapy naive were enrolled onto the phase
2 portion of the study. All patients had to be  18 years of age, have
an Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1 (phase 1) or  2 (phase 2), and measurable disease
according to the Response Evaluation Criteria in Solid Tumors
(RECIST) (phase 2). Adequate hematologic and organ function
were also required. Key exclusion criteria included known hyper-
sensitivity to monoclonal antibody therapy, maytansinoids, or eto-
poside; a history of allergic reaction to platinum-containing
compounds; > 3 prior cytotoxic regimens (phase 1 only); or a
previous malignancy with < 3-year disease-free interval other than
basal-cell or squamous-cell carcinoma, or in-situ cervical, breast, or
prostate cancer. Patients with symptomatic central nervous system
(CNS) metastases or asymptomatic CNS metastases requiring
concurrent corticosteroid therapy were excluded from phase 1. For
phase 2, patients with CNS metastases were excluded unless pre-
viously treated with surgery or radiotherapy and receiving therapy
with stable, decreasing, or no steroids. All patients provided written
informed consent in accordance with federal, local, and/or institu-
tional guidelines.
Study Design
This open-label multicenter phase 1/2 study was conducted in 45
centers in the United States, Spain, Canada, and the United
Kingdom. The study was conducted in accordance with the US
Food and Drug Administration regulations, the International
Conference on Harmonisation Guidelines for Good Clinical Prac-
tice, and the Declaration of Helsinki. The study was compliant with
institutional review board and independent ethics committee re-
quirements. The trial was registered at ClinicalTrials.gov
(NCT01237678).
The phase 1 portion followed a traditional 3 þ 3 dose esca-
lation design exploring escalating doses of LM in combination
with carboplatin/etoposide to determine the maximum tolerated
dose (MTD). LM was administered as an intravenous (I.V.)
infusion on days 1 and 8 of a 21-day cycle in combination with
carboplatin/etoposide. This schedule was identical to that eval-
uated in a prior phase 1 monotherapy study in patients with
CD56-positive myeloma (NCT00346255) and shown to have
favorable tolerability. The starting dose of LM was 60 mg/m2,
which was 3 dose levels below the established MTD (112 mg/
m2) on this regimen; dose escalation proceeded, as tolerated,
through 75 mg/m2, 90 mg/m2, and 112 mg/m2. The starting
dose of carboplatin was at an AUC (area under the plasma
concentration vs. time curve) of 6; however, because of poor
tolerability, this was reduced to an AUC of 5. Treatment
continued for 4 cycles, with up to 6 cycles allowed. Patients
Mark A. Socinski et alwhose disease responded to treatment or patients with stable
disease (SD) were eligible to receive single-agent LM treatment
until disease progression or unacceptable toxicity. The MTD was
determined on the basis of dose-limiting toxicities (DLTs) that
occurred during cycle 1. A total of 12 patients were treated at the
MTD to determine the recommended phase 2 dose (RP2D);
after these patients had completed cycle 1, the phase 2 portion of
the study commenced.
ED-SCLC patients participating in the phase 2 study were
randomly assigned at a 2:1 ratio to arm 1 (LM þ carboplatin þ
etoposide) or arm 2 (carboplatin þ etoposide alone). Treatment
in arm 1 proceeded as follows: intravenous LM on days 1 and 8
at the RP2D (initially 112 mg/m2, reduced by protocol
amendment to 90 mg/m2), plus carboplatin I.V. at an AUC of 5
on day 1 and etoposide 100 mg/m2 I.V. on days 1, 2, and 3 in
each 21-day treatment cycle. In arm 2, carboplatin was admin-
istered at an AUC of 5 on day 1 and etoposide at a dose of 100
mg/m2 on days 1, 2, and 3 of each 21-day treatment cycle.
Carboplatin and etoposide were administered for up to 6 cycles
as tolerated.
Assessments
Baseline assessments included medical history, vital signs, phys-
ical and neurologic examination, ECOG performance status, blood
chemistry and hematology, serum pregnancy test, and electrocar-
diogram. During screening, radiologic imaging of the chest,
abdomen, and pelvis (if applicable) was performed. In addition,
baseline brain imaging (magnetic resonance imaging or computed
tomography) and bone scans were required for all SCLC patients in
order to determine the presence of brain metastases and bone
involvement, respectively. Target and nontarget lesions were iden-
tiﬁed and recorded per RECIST version 1.1.23
All patients who received at least one dose of study drug and had
at least one postbaseline safety assessment were included in the
Safety Population analyses. Adverse events (AEs) were graded ac-
cording to the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.0, and monitored continu-
ously throughout the study from the time of the ﬁrst study dose
until 28 days after treatment cessation.
Efﬁcacy parameters included objective response rate (ORR),
progression-free survival (PFS), and OS up to 12 months. Efﬁcacy
analyses were conducted on the intent-to-treat population (all pa-
tients who signed the informed consent and had at least one post-
baseline efﬁcacy evaluation). PFS was deﬁned as the time from
enrollment to disease progression via RECIST 1.1 or death for any
cause. OS was deﬁned as the time from enrollment to death or
censored at the date last known to be alive.
Blood samples for pharmacokinetic characterization of LM, car-
boplatin, and etoposide were collected from all patients at pre-
speciﬁed time points during the ﬁrst and fourth treatment cycles in
phase 1. Plasma concentrations of LM (as well as total huN901
antibody) were assayed by enzyme-linked immunosorbent assay.
Carboplatin and etoposide levels in plasma were measured by vali-
dated liquid chromatographyetandem mass spectrometry methods.
Standard noncompartmental pharmacokinetic evaluation was per-
formed by WinNonlin Professional 6.1.0.173 software (Pharsight,
Mountain View, CA).Statistical Analysis
The primary end point of phase 1 of the study was occurrence of
DLTs as a function of the dose of LM when administered in
combination with carboplatin þ etoposide. No formal sample size
calculation was performed for phase 1. The primary end point in
phase 2 was PFS. For design purposes, the number of patients who
were free of progression at 6 months was used to test hypotheses
against historical 6-month PFS rates typically seen in patients
treated with carboplatin þ etoposide. Thus, the study was not
powered to permit a statistically informative comparison of the
randomized treatment groups with respect to PFS or OS. In phase
2, a 2-stage design was used, with 39 and 41 patients planned for
treatment in the experimental arm in stages 1 and 2, respectively.
For stage 1, if fewer than 18 patients were free of progression at 6
months, the trial was to be stopped and IMGN901 declared
insufﬁciently active. On the basis of the estimated sample size (80
patients), the lower limit of the 1-sided 95% conﬁdence interval
(CI) for a 6-month PFS rate was equal to at least 40%.
Descriptive statistics for continuous variables were summarized
using sample size, mean, median, standard deviation, minimum,
and/or maximum. All descriptive analyses were performed by SAS
statistical software version 9.2 or later (SAS Institute, Cary, NC).
For the safety population evaluations, any event with the same onset
date as start of study treatment or later was reported as treatment
emergent. Baseline was deﬁned as the last available assessment
before day 1, cycle 1.
Time-to-event variables (PFS and OS) were analyzed by Kaplan-
Meier estimates, including calculation of median and 95% CIs; the
OS rate at 12 months and PFS rate at 6 months were also deter-
mined. All response-evaluable patients who had a postbaseline
assessment were included in the ORR (conﬁrmed and unconﬁrmed)
and disease control rate (complete response [CR], partial response
[PR], or SD) analyses, along with the corresponding exact 95% CIs
based on the Clopper-Pearson method. Best overall responses (CR,
unconﬁrmed CR, PR, unconﬁrmed PR, SD, or progressive disease)
were tabulated.
Results
Patient Characteristics
Between November 2010 and May 2015, a total of 33 and 148
patients were enrolled onto the phase 1 and 2 portions of the study,
respectively. For phase 2, a total of 98 patients were randomly
assigned to arm 1 (LM þ carboplatin þ etoposide) and 50 to arm 2
(carboplatin þ etoposide alone). Fifty-two patients enrolled onto
arm 1 received LM at the RP2D of 112 mg/m2; the remaining 46
were enrolled after a protocol amendment and received LM at 90
mg/m2. Overall, 141 patients in phase 2 received at least one dose of
study drug and had at least one postbaseline safety assessment and
were included in the safety population (ie, n ¼ 94 in arm 1 and n ¼
47 in arm 2). Patient baseline characteristics are summarized in
Table 1. Extended details for the phase 1 population are presented
in Supplemental Table 1 (in the online version).
The majority of patients enrolled onto the phase 1 portion of the
study were women (61%), white (91%), and had a diagnosis of lung
cancer (52%). The median age of this cohort was 59 years (range, 25-
81 years). Most individuals had received prior systemic (82%) and/or
radiotherapy (55%), and 42% had undergone surgery. For phase 2,Clinical Lung Cancer Month 2016 - 3
Table 1 Patient Demographic and Baseline Characteristics
Characteristic
Phase 1 (Carboplatin/
Etoposide D LM), Total
Phase 2
Arm 1 Arm 2
Carboplatin/Etoposide D LM
(112 mg/m2)
Carboplatin/Etoposide D LM
(90 mg/m2) Total
Carboplatin/
Etoposide
Number 33 50 44 94 47
Age, Years
Median (range) 59 (25-81) 65.0 (43-80) 63.0 (43-90) 63.5 (43-90) 64.0 (40-82)
Gender
Male 13 (39.4) 31 (62.0) 23 (52.3) 54 (57.4) 25 (53.2)
Female 20 (60.6) 19 (38.0) 21 (47.7) 40 (42.6) 22 (46.8)
Racea
White 30 (90.9) 47 (98.0) 43 (97.7) 90 (95.7) 44 (93.6)
Black or African
American
2 (6.1) 3 (6.0) 0 3 (3.2) 2 (4.3)
Asian 0 0 1 (2.3) 1 (1.1) 0
American
Indian/Alaska Native
1 (3.0) 0 0 0 0
Unknown 0 0 0 0 1 (2.1)
ECOG PS
0 14 (42.4) 13 (26.0) 9 (20.5) 22 (23.4) 12 (25.5)
1 19 (57.6) 32 (64.0) 30 (68.2) 62 (66.0) 32 (68.1)
2 - 5 (10.0) 5 (11.4) 10 (10.6) 3 (6.4)
Tobacco Smoking
History of smoking 21 (63.6) 50 (100.0) 43 (97.7) 93 (98.9) 46 (97.9)
Currently smoking 6 (18.2) 19 (38.0) 16 (36.4) 35 (37.2) 13 (27.7)
Prior Therapy
Surgery 14 (42.4) 0 2 (4.5) 2 (2.1) 2 (4.3)
Radiotherapy 18 (54.5) 1 (2.0) 9 (20.5) 10 (10.6) 3 (6.4)
Systemic therapy 27 (81.8) 0 0 0 1 (2.1)
Data are presented as n (%) unless otherwise indicated.
Abbreviations: C/E ¼ carboplatin/etoposide; LM ¼ lorvotuzumab mertansine.
aIncludes individuals of Hispanic or Latino origin.
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were similar between arms. One patient in arm 2 had received one
prior systemic therapy (5-ﬂuorouracil plus leucovorin) for the treat-
ment of colon cancer more than 3 years before study enrollment; the
remaining 140 patients had received no prior systemic therapy.
Phase 1 Study: Exposure, Safety, and Efﬁcacy
All 33 patients enrolled onto the phase 1 cohort were included in
the analyses. Seven patients (21%) experienced a DLT in cycle 1,
consisting primarily of hematologic toxicities. All 3 patients treated
with 75 mg/m2 LM and carboplatin at an AUC of 6 reported DLTs
related to myelosuppression, including febrile neutropenia, throm-
bocytopenia, and granulocytopenia (grades 3 and 4). Therefore, the
carboplatin dose was reduced to an AUC of 5, and escalation
continued to the maximum planned LM dose of 112 mg/m2. Only
2 of 12 patients reported a DLT at the 112 mg/m2 dose level, and
this dose was declared the RP2D.
The mean number of cycles that patients received during phase 1
was 4.3 (range, 1-10 cycles), with 55% receiving at least 4 cycles of
therapy. Reduction of the carboplatin dose from an AUC of 6 to annical Lung Cancer Month 2016AUC of 5 improved the overall tolerability of the combination
regimen and resulted in a longer mean duration of dosing, greater
number of cycles administered, and higher mean cumulative doses
for patients receiving comparable LM doses.
All phase 1 patients experienced at least one treatment-emergent
adverse event (TEAE), with gastrointestinal disorders and hemato-
logic events being the most commonly reported. In addition, 58%
of patients experienced at least one peripheral neuropathy event,
including paresthesia, peripheral sensory neuropathy, neuropathy
peripheral, peripheral motor neuropathy, neurotoxicity, and neu-
ralgia, the majority of which were grade 1 or 2 in severity. The most
commonly reported treatment-related TEAEs were anemia (55% of
patients), peripheral sensory neuropathy (52%), thrombocytopenia
(48%), fatigue (45%), and nausea (33%). Table 2 summarizes grade
3 and 4 treatment-related TEAEs reported for > 10% of patients.
Thirty-three percent of the patients experienced at least one grade 4
TEAE; the most common were hematologic abnormalities,
including thrombocytopenia (21%) and neutropenia (12%). In
addition, grade 4 febrile neutropenia and leukopenia were observed
in 3 patients each (9%).
Table 2 Incidence of Grade 3 and 4 Treatment-Related, Treatment-Emergent Adverse Events Reported in > 10% of Phase 1 Patients
Characteristic
Carboplatin (AUC 6) D Etoposide Carboplatin (AUC 5) D Etoposide
Total
D LM
60 mg/m2
D LM
75 mg/m2
D LM
75 mg/m2
D LM
90 mg/m2
D LM
112 mg/m2
No. of TEAEs 6 6 3 6 12 33
No. of Patients With Any
Treatment-Related TEAEs
Grade 3 3 (50.0) 3 (50.0) 1 (33.3) 4 (66.7) 8 (66.7) 19 (57.6)
Grade 4 3 (50.0) 3 (50.0) 0 2 (33.3) 3 (25.0) 11 (33.3)
Thrombocytopenia
Grade 4 2 (33.3) 2 (33.3) 0 2 (33.3) 1 (8.3) 7 (21.2)
Anemia
Grade 3 1 (16.7) 2 (33.3) 0 2 (33.3) 2 (16.7) 7 (21.2)
Neutropenia
Grade 3 2 (33.3) 0 0 1 (16.7) 2 (16.7) 5 (15.2)
Grade 4 0 1 (16.7) 0 1 (16.7) 2 (16.7) 4 (12.1)
Lymphocyte Count Decreased
Grade 3 0 1 (16.7) 1 (33.3) 0 3 (25.0) 5 (15.2)
White Blood Cell Count Decreased
Grade 3 0 1 (16.7) 0 0 4 (33.3) 5 (15.2)
Lymphopenia
Grade 3 2 (33.3) 0 0 2 (33.3) 0 4 (12.1)
Data are presented as n (%) unless otherwise indicated.
Abbreviations: AUC ¼ area under the curve; LM ¼ lorvotuzumab mertansine; TEAE ¼ treatment-emergent adverse event.
Mark A. Socinski et alDuring phase 1, TEAEs led to study treatment discontinuation
in 24% of the patients, although no clear relationship with the study
drug dose was seen. A low incidence (6%) of serious infections
(sepsis) was observed in 2 patients enrolled onto phase 1; one case
(grade 4) was considered possibly related to study drug, and the
other was fatal but deemed unrelated to the study drug.
The conﬁrmed ORR in the phase 1 population was 18%. All
patients contributing to theORR(4cases of lung, 1 colon, and1ovarian
cancer) had a conﬁrmed PR, with no CRs observed. Thirty-six percent
of the patients had SD; thus, the overall disease control rate was 64%.Table 3 Summary of Plasma Pharmacokinetic Parameters for Lorvo
Carboplatin and Etoposide (Cycle 1)
Dose Group (mg/m2) Cmax, mg/mL t1/2 , Ho
Cycle 1, Day 1
60 (n ¼ 6) 32.6 (4.4) 16.0 (1
75 (n ¼ 9) 39.7 (9.1) 17.5 (4
90 (n ¼ 6) 50.7 (5.0) 15.8 (2
112 (n ¼ 12) 54.0 (14.5) 16.3 (2
Cycle 1, Day 8
60 (n ¼ 6) 31.9 (9.8) 15.9 (3
75 (n ¼ 9) 37.0 (5.9) 17.7 (3
90 (n ¼ 6) 47.5 (5.8) 15.0 (2
112 (n ¼ 12) 46.8 (13.4) 15.0 (2
Data are presented as means (standard deviation).
Abbreviation: AUC ¼ area under the curve.Pharmacokinetics
A secondary objective of the phase 1 component was to deter-
mine LM pharmacokinetics when the triplet combination was
provided to patients with solid tumors. Data for cycle 1 are pre-
sented that show that Cmax and AUC values all increased in relative
proportion to dose (Table 3), and an analogous proﬁle was seen for
total huN901 antibody measurements (data not shown). Day 1 and
8 concentration proﬁles were similar, and there was no apparent
drug accumulation for these once-weekly doses. The mean apparent
elimination half-life (t1/2 ) of LM following the ﬁrst drugtuzumab Mertansine After Infusion in Combination With
urs AUC0-t, h*mg/mL AUC0-N, h*mg/mL
.0) 606 (106) 674 (97)
.9) 752 (245) 947 (329)
.1) 885 (192) 1033 (178)
.2) 917 (202) 1090 (246)
.2) 444 (128) 728 (289)
.8) 518 (108) 941 (162)
.3) 657 (63) 1022 (120)
.0) 627 (225) 1033 (227)
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Table 4 Summary of Treatment-Related Adverse Events (All Grades) in Phase 2 Safety Population (n [ 141)
Characteristic
Arm 1, N (%) Arm 2, N (%)
C/E D LM (112 mg/m2) C/E D LM (90 mg/m2) Totala C/E
Number 50 44 94 47
Any TEAE 50 (100.0) 44 (100.0) 94 (100.0) 46 (97.9)
Related TEAE 49 (98.0) 41 (93.2) 90 (95.7) 39 (83.0)
Any SAE 30 (60.0) 24 (54.5) 54 (57.4) 23 (48.9)
Related SAE 21 (42.0) 9 (20.5) 30 (31.9) 9 (19.1)
TEAEs leading to treatment
discontinuationb
34 (68.0) 16 (36.4) 50 (53.2) 6 (12.8)
Any grade 3 or higher TEAE 48 (96.0) 44 (100) 92 (97.9) 42 (89.4)
Related grade 3 or higher TEAE 46 (92.0) 37 (84.1) 83 (88.3) 33 (70.2)
TEAE with outcome of death 7 (14.0) 11 (25.0) 18 (19.1) 3 (6.4)
Abbreviations: C/E ¼ carboplatin/etoposide; LM ¼ lorvotuzumab mertansine; SAE ¼ serious adverse event; TEAE ¼ treatment-emergent adverse event.
aIncludes patients treated at starting doses of LM of 112 and 90 mg/m2.
bAEs are summarized only for subjects with primary reason for treatment discontinuation of adverse event.
Study of Lorvotuzumab Mertansine
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remained consistent across both dose level and intracycle dosing.
Phase 2 Study: Safety and Tolerability
The SCLC patients enrolled onto arm 1 received a mean of 5
cycles of study drug (range, 1-20 cycles). Sixty-six percent of the
patients in arm 1 and 60% in arm 2 received at least 4 cycles of the
study drug. As per protocol, no patient in arm 2 received more than
6 cycles. The initial 52 patients enrolled onto arm 1 received LM at
the RP2D determined in phase 1 (112 mg/m2); however, as a result
of an increased frequency of peripheral neuropathy events in this
population, the protocol was amended to increase the sample size,
and 46 additional patients who were subsequently enrolled received
LM at a reduced dose of 90 mg/m2.
Serious adverse events (SAEs) were reported for 57% of patients
in arm 1 and 49% in arm 2; of these, 32% and 19% were assessed
as treatment related, respectively (Table 4). The most common
SAEs observed among LM-treated patients were febrile neutropenia
(6%), pneumonia (5%), neutropenia (3%), neutropenic sepsis
(3%), peripheral sensory neuropathy (3%), and septic shock (3%).
The prevalence of these SAEs was lower among patients treated with
carboplatin/etoposide alone, with the exception of febrile neu-
tropenia (11%) and diarrhea (4%). A total of 21 patients (18
enrolled onto arm 1 and 3 in arm 2) had a TEAE with an outcome
of death. For 10 patients (9 in arm 1 and 1 in arm 2), the TEAE was
an infection (either pneumonia or a septic event) deemed to be
related to study drug (Supplemental Table 2 in the online version).
As shown in Table 4, almost all patients in the phase 2 study
population (n ¼ 141) experienced at least one TEAE. The most
commonly observed TEAEs were gastrointestinal disorders and
hematologic events, as well as general disorders and administration-
site conditions. Treatment discontinuations due to TEAEs were
higher among patients enrolled onto arm 1 (53%) compared to
those reported among patients enrolled onto arm 2 (13%). The
most common type of TEAEs leading to discontinuation were pe-
ripheral neuropathy events (29%). Of note, patients receiving LM
at 90 mg/m2 showed both a slightly lower overall incidence of pe-
ripheral neuropathy compared to those receiving LM at 112 mg/m2
(73% vs. 86%) as well as fewer grade 3 events (11% vs. 36%).nical Lung Cancer Month 2016The incidence of study treatment-related TEAEs was 96% in arm
1 and 83% in arm 2. Table 5 summarizes those reported for > 10%
of the phase 2 SCLC population. Nervous system disorders were
more frequently reported in patients who received LM (arm 1),
including peripheral sensory neuropathy (61%) and paraesthesia
(21%); patients enrolled onto arm 2 experienced a lower incidence
of these events. Other treatment-related TEAEs occurring at a
substantially higher incidence in arm 1 compared to arm 2 included
fatigue, diarrhea, arthralgia, and increased alanine aminotransferase
levels (Table 5). In total, 88% of arm 1 and 70% of arm 2 patients
experienced a grade 3 or 4 TEAE that was deemed to be treatment
related. The majority of grade 3 events were clinical laboratory
abnormalities and included anemia (19%), peripheral sensory
neuropathy (18%), neutropenia (17%), and thrombocytopenia
(11%) (Supplemental Table 3 in the online version). Their inci-
dence was similar in each arm, with the exception of peripheral
sensory neuropathy, which occurred at a higher frequency in arm 1
compared to arm 2. Further, apart from neutropenia (32%), the
occurrence of speciﬁc grade 4 TEAEs was low (< 6.5%).
Efﬁcacy
For phase 2, efﬁcacy analyses were performed on a total of 121
patients (82 in arm 1 and 39 in arm 2) as a result of a lack of
postbaseline evaluations for 20 patients from the safety population.
Median PFS was similar in both study arms: 6.2 months (95% CI,
5.4-7.2) for the combination regimen compared to 6.7 months
(95% CI, 5.3-7.5) for carboplatin þ etoposide alone (Figure 1A)
with a hazard ratio of 0.93 (95% CI, 0.58-1.51). On the basis of
Kaplan-Meier estimates, the median OS for arms 1 and 2 were 10.1
months (95% CI, 8.7-18.1) and 11.0 months (95% CI, 7.5-11.4),
respectively (Figure 1B).
The ORR (conﬁrmed and unconﬁrmed) for the 82 patients in
arm 1 was 67% (95% CI, 55.8-77.1, with conﬁrmed CR and PR
rates of 4% and 61%, respectively) compared to 59% (95% CI,
42.1-74.4) for the 39 patients in arm 2 (Figure 2). The median time
to conﬁrmed responses in arm 1 was short (1.4 months), and the
median duration of response was 6.1 months (95% CI, 4.9-7.1).
Eleven patients (13%) had SD as best response; therefore the disease
control rate, based on conﬁrmed and unconﬁrmed best overall
Table 5 Common Treatment-Related, Treatment-Emergent Adverse Events (All Grades) Reported in > 10% of Phase 2 SCLC Patients
Characteristic
Arm 1, N (%) Arm 2, N (%)
C/E D LM (112 mg/m2) C/E D LM (90 mg/m2) Total C/E
Number 50 44 94 47
Blood and Lymphatic System 41 (82.0) 33 (75.0) 74 (78.7) 31 (66.0)
Anemia 20 (40.0) 24 (54.5) 44 (46.8) 21 (44.7)
Febrile neutropenia 4 (8.0) 5 (11.4) 9 (9.6) 7 (14.9)
Leukopenia 5 (10.0) 3 (6.8) 8 (8.5) 6 (12.8)
Neutropenia 30 (60.0) 18 (40.9) 48 (51.1) 22 (46.8)
Thrombocytopenia 15 (30.0) 14 (31.8) 29 (30.9) 19 (40.4)
Gastrointestinal 38 (76.0) 28 (63.6) 66 (70.2) 23 (48.9)
Constipation 6 (12.0) 4 (9.1) 10 (10.6) 3 (6.4)
Diarrhea 14 (28.0) 11 (25.0) 25 (26.6) 6 (12.8)
Nausea 21 (42.0) 12 (27.3) 33 (35.1) 14 (29.8)
Vomiting 7 (14.0) 5 (11.4) 12 (12.8) 8 (17.0)
General Disorders and
Administration Site
37 (74.0) 25 (56.8) 62 (66.0) 25 (53.2)
Asthenia 13 (26.0) 9 (20.5) 22 (23.4) 10 (21.3)
Fatigue 22 (44.0) 17 (38.6) 39 (41.5) 11 (23.4)
Mucosal inﬂammation 7 (14.0) 2 (4.5) 9 (9.6) 6 (12.8)
Infections and infestations 10 (20.0) 8 (18.2) 18 (19.1) 9 (19.1)
Investigations 24 (48.0) 18 (40.9) 42 (44.7) 15 (31.9)
Alanine aminotransferase increased 4 (8.0) 6 (13.6) 10 (10.6) 0
Neutrophil count decreased 5 (10.0) 6 (13.6) 11 (11.7) 7 (14.9)
Platelet count decreased 7 (14.0) 8 (18.2) 15 (16.0) 6 (12.8)
Metabolism and Nutrition System 19 (38.0) 19 (43.2) 38 (40.4) 18 (38.3)
Decreased appetite 15 (30.0) 9 (20.5) 24 (25.5) 15 (31.9)
Hypomagnesemia 3 (6.0) 8 (18.2) 11 (11.7) 1 (2.1)
Musculoskeletal and Connective
Tissue
23 (46.0) 9 (20.5) 32 (34.0) 3 (6.4)
Arthralgia 9 (18.0) 2 (4.5) 11 (11.7) 0
Nervous System 45 (90.0) 31 (70.5) 76 (80.9) 11 (23.4)
Paraesthesia 14 (28.0) 6 (13.6) 20 (21.3) 2 (4.3)
Peripheral sensory neuropathy 32 (64.0) 25 (56.8) 57 (60.6) 2 (4.3)
Skin and Subcutaneous Tissue 18 (36.0) 8 (18.2) 26 (27.7) 16 (34.0)
Alopecia 13 (26.0) 6 (13.6) 19 (20.2) 16 (34.0)
Vascular disorders 7 (14.0) 5 (11.4) 12 (12.8) 3 (6.4)
Abbreviations: C/E ¼ carboplatin/etoposide; LM ¼ lorvotuzumab mertansine; SCLC ¼ small-cell lung cancer.
Mark A. Socinski et alresponses, was 92% in arm 1, which was comparable to the 95%
observed for arm 2.
Discussion
Conventional chemotherapeutic approaches for the treatment of
SCLC have largely reached a plateau of effectiveness, and the
prognosis for individuals with metastatic disease remains dismal,
with 2-year survival rates of less than 5%.24 One strategy for
improving patient outcomes is through the use of new drugs with
novel mechanisms of action in combination with established ﬁrst-
line chemotherapy. In preclinical models, LM was shown to
potentiate the antitumor activity of standard-of-care platinum/eto-
poside doublets in SCLC xenografts.21 In addition, preliminary
signs of efﬁcacy were observed in SCLC patients who underwentLM monotherapy.22 In light of these considerations, this multi-
center phase 1/2 study was undertaken in order to evaluate the
clinical activity and toxicity of LM in combination with carboplatin/
etoposide chemotherapy in patients with ED-SCLC.
The phase 1 portion of the study accrued 33 patients with
advanced solid tumors who had experienced disease progression
despite prior therapy, the majority of which were lung cancers. The
DLTs to emerge during the dose-ﬁnding stage consisted primarily of
hematologic toxicities, including febrile neutropenia, thrombocy-
topenia, and granulocytopenia. Because myelosuppression is an
established toxicity of carboplatin exposure in SCLC patients,25 the
carboplatin dose was reduced from an AUC of 6 to an AUC of 5.
LM dose escalation then continued to the maximum planned dose
of 112 mg/m2, which was initially declared the RP2D; this wasClinical Lung Cancer Month 2016 - 7
Figure 1 Kaplan-Meier Curves for (A) Progression-Free and (B)
Overall Survival
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio.
Figure 2 Best Overall Response
Abbreviation: NE ¼ not evaluable.
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higher incidence of peripheral neuropathy-associated AEs.
The TEAEs observed in both phases of the study were consistent
with the previously reported proﬁles for single-agent LM as well as
carboplatin/etoposide. In this regard, peripheral neuropathy was an
expected AE, and the incidence seen in this study was comparable to
that observed in a separate trial of multiple myeloma patients treated
with LM in combination with lenalidomide and dexamethasone.26
However, for phase 2, peripheral neuropathies were both the most
commonly reported and the most common drug-related TEAEs
leading to study discontinuation. Moreover, the frequency of events
was notably higher in arm 1 compared to arm 2. These results
suggest that combinations of LM with carboplatin, a drug itself
known to cause peripheral neuropathy,27 augment both the degree
and severity of such symptoms in patients undergoing therapy.
On the basis of the safety results from earlier clinical trials eval-
uating LM, as either monotherapy or as part of combination regi-
mens,22,26 the high incidence and fatal outcomes of serious
infection events in patients receiving the triple combination was
unexpected. Myelosuppression is a known side effect of carboplatin,
and it has been shown to increase susceptibility to infection.25,28
However, serious infections and associated deaths were rare in thenical Lung Cancer Month 2016carboplatin/etoposide arm. The increase in fatal outcomes of serious
infection events by the triplet combination underscored the chal-
lenges of combining agents with known hematologic toxicities.
However, it is important to note that no relationship between LM
dose and the infection rate was seen. However, it is clear that the
triplet regimen is a risk factor because no serious infections were
reported in patients receiving LM as single agent during the course
of this trial.
The primary objective of the phase 2 portion of the study was to
determine the efﬁcacy of LM plus carboplatin/etoposide combina-
tion treatment in chemotherapy-naive patients with ED-SCLC. A
minor improvement in response rate was seen in the combination
arm (67%) relative to carboplatin/etoposide doublet therapy (59%),
including more conﬁrmed CRs and PRs. However, the median PFS
for patients treated with the triplet combination was not signiﬁcantly
different from that seen for those in the carboplatin/etoposide-
treated arm (6.2 vs. 6.7 months, respectively), and a projected
improvement of 2.5 months from historical controls was not ach-
ieved. In terms of OS, median OS for combination-treated patients
was 10.1 months, which falls in between the OS rates of 9.8 and 11
months reported for similar ED-SCLC patient populations.29,30
Conclusion
The addition of LM to carboplatin/etoposide doublet therapy
failed to confer a signiﬁcant PFS or OS advantage in previously un-
treated ED-SCLC patients. While the toxicities seen with combina-
tion treatment reﬂected those previously reported for LM and
carboplatin, a higher incidence of serious infections with fatal out-
comes was observed in patients receiving the triplet regimen. Thus,
the addition of LM to a carboplatin/etoposide regimen administered
on the schedule and doses evaluated herewas associatedwith increased
safety risks without a clear signal of beneﬁt. This combination should
not be considered for further development in ED-SCLC.
Clinical Practice Points
 The smoking-related malignancy SCLC remains a clinical chal-
lenge for the practicing oncologist, with the typical patient
diagnosed being elderly and with many other comorbid illnesses.
Mark A. Socinski et al The standard of care remains platinum plus etoposide chemo-
therapy for 4 to 6 cycles, a modality that not changed the survival
outlook for ED-SCLC patients in more than 2 decades. A
number of strategies designed to improve survival outcomes have
been explored, including the addition of a third drug to the
platinum/etoposide combination; however, to date, none has
provided meaningful clinical beneﬁt with an acceptable rate of
toxicity.
 LM is a CD56-targeting antibody-drug conjugate developed for
tumor-selective delivery of the cytotoxic maytansinoid DM1. This
phase 1/2 trial sought to integrate this novel agent into the car-
boplatin plus etoposide regimen in ED-SCLC. Unfortunately, no
signiﬁcant improvements in efﬁcacy measures were observed, and
SAEs leading to death were seen with the triplet combination.
 Improving outcomes in ED-SCLC will require new therapeutic
strategies, beginning with a better understanding of the basic
biologic pathways operative in this disease, which remain among
the most recalcitrant malignancies seen in clinical practice.Acknowledgments
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Supplemental Table 2 Treatment-Related Adverse Events in Phase 2 Study With Outcome of Death
Adverse Event Arm 1 (N [ 9) Arm 2 (N [ 1)
Neutropenic sepsis 1 0
Pneumonia 3 0
Sepsis 2 1
Septic shock 3 0
Supplemental Table 1 Patient Demographic and Baseline Characteristics for Phase 1 Study (Safety Population)
Characteristic
Carboplatin (AUC 6) D Etoposide Carboplatin (AUC 5) D Etoposide
Total
D LM
60 mg/m2
D LM
75 mg/m2
D LM
75 mg/m2
D LM
90 mg/m2
D LM
112 mg/m2
Number 6 6 3 6 12 33
Age, Years
Median (range) 55.0 (25-70) 70.0 (34-81) 63.0 (47-66) 59.0 (47-68) 54.5 (33-72) 59.0 (25-81)
Gender
Male 4 (66.7) 2 (33.3) 2 (66.7) 1 (16.7) 4 (33.3) 13 (39.4)
Female 2 (33.3) 4 (66.7) 1 (33.3) 5 (83.3) 8 (66.7) 20 (60.6)
Racea
White 6 (100) 4 (66.7) 3 (100.0) 5 (83.3) 12 (100.0) 30 (90.9)
Black or African American 0 1 (16.7) 0 1 (16.7) 0 2 (6.1)
American Indian/Alaska Native 0 1 (16.7) 0 0 0 1 (3.0)
Primary Tumor Site
Lung 2 (33.3) 3 (50.0) 2 (66.7) 4 (66.7) 6 (50.0) 17 (51.5)
Colon 0 0 0 1 (16.7) 1 (8.3) 2 (6.1)
Ovary 0 1 (16.7) 1 (33.3) 0 0 2 (6.1)
Vulva 0 1 (16.7) 0 0 1 (8.3) 2 (6.1)
Kidney 1 (16.7) 0 0 0 0 1 (3.0)
Uterus 0 0 0 1 (16.7) 0 1 (3.0)
Cervix 0 0 0 0 1 (8.3) 1 (3.0)
Merkel-cell carcinoma 0 1 (16.7) 0 0 0 1 (3.0)
Scalp and neck 1 (16.7) 0 0 0 0 1 (3.0)
HNSCC 0 0 0 0 1 (8.3) 1 (3.0)
Thymus 0 0 0 0 1 (8.3) 1 (3.0)
Unknown 2 (33.3) 0 0 0 1 (8.3) 3 (9.1)
ECOG PS
0 4 (66.7) 2 (33.3) 0 3 (50.0) 5 (41.7) 14 (42.4)
1 2 (33.3) 4 (66.7) 3 (100.0) 3 (50.0) 7 (58.3) 19 (57.6)
Tobacco Smoking
No. with history of smoking 4 3 1 4 9 21
Currently smoking 1 (16.7) 1 (16.7) 0 2 (33.3) 2 (16.7) 6 (18.2)
Prior Therapy
Surgery 1 (16.7) 3 (50.0) 2 (66.7) 2 (33.3) 6 (50.0) 14 (42.4)
Radiotherapy 3 (50.0) 4 (66.7) 0 4 (66.7) 7 (58.3) 18 (54.5)
Systemic therapy 5 (83.3) 6 (100.0) 2 (66.7) 5 (83.3) 9 (75.0) 27 (81.8)
Data are presented as n (%) unless otherwise indicated.
Abbreviations: AUC ¼ area under the curve; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; HNSCC ¼ head and neck squamous-cell carcinoma; LM ¼ lorvotuzumab
mertansine.
aIncludes individuals of Hispanic or Latino origin.
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Supplemental Table 3 Common Grade 3 and 4 Treatment-Related, Treatment-Emergent Adverse Events Reported in > 10% of Phase
2 SCLC Patients
Characteristic
Arm 1, N (%) Arm 2, N (%)
C/E D LM (112 mg/m2) C/E D LM (90 mg/m2) Total C/E
No. of TEAEs 50 44 94 47
Patients With Any Treatment-Related
TEAEs
Grade 3 37 (74.0) 33 (75.0) 70 (74.5) 30 (63.8)
Grade 4 24 (48.0) 21 (47.7) 45 (47.9) 21 (44.7)
Neutropenia
Grade 3 12 (24.0) 4 (9.1) 16 (17.0) 8 (17.0)
Grade 4 17 (34.0) 13 (29.5) 30 (31.9) 13 (27.7)
Anemia
Grade 3 8 (16.0) 10 (22.7) 18 (19.1) 10 (21.3)
Peripheral Sensory Neuropathy
Grade 3 12 (24.0) 5 (11.4) 17 (18.1) 0
Thrombocytopenia
Grade 3 4 (8.0) 6 (13.6) 10 (10.6) 5 (10.6)
Grade 4 4 (8.0) 2 (4.5) 6 (6.4) 5 (10.6)
Neutrophil Count Decreased
Grade 4 2 (4.0) 4 (9.1) 6 (6.4) 6 (12.8)
Febrile Neutropenia
Grade 3 1 (2.0) 2 (4.5) 3 (3.2) 6 (12.8)
Abbreviations: C/E ¼ carboplatin/etoposide; LM ¼ lorvotuzumab mertansine; SCLC ¼ small-cell lung cancer; TEAE ¼ treatment-emergent adverse event.
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